Glucotrack picks up new patents for continuous blood glucose monitor
January 29, 2026
Glucotrack (Nasdaq:GCTK) announced today that it received new U.S. patents for its continuous blood glucose monitoring (CBGM) platform.
Glucotrack (Nasdaq:GCTK) announced today that it received new U.S. patents for its continuous blood glucose monitoring (CBGM) platform.
From M&A to surgical robotics and user fee negotiations, the medical device industry has a busy year ahead. Check out MedTech Dive’s roundup of the top medtech trends to watch in 2026.
The FDA has authorised up to 15 clinical sites to take part in the study.
Imperative Care announced the launch of the new Zoom 4S thrombectomy catheter and reported the first patient cases with the device.
Pulsed-field ablation, transcatheter heart valves, and intravascular lithotripsy are among the top stories, as they drive growth among the largest cardio device companies.
Siemens Healthineers announced today that it received FDA clearance for its Biograph One second-generation PET/MR scanner.
Senseonics (NYSE:SENS) announced today that its Eversense 365 continuous glucose monitor (CGM) system received CE mark approval.
The CE Mark certification enables Seno Medical to market and sell the latest version of its Imagio® Imaging System with opto-acoustic, sound, and artificial intelligence in the European Union.
Extracellular vesicles (EVs) are tiny particles shed by cells that carry important molecular “clues” about the cell’s identity and condition.
Euan Ashley’s lab explores the intricate interactions of gene variants. Tiny “typos,” or genetic mutations, can sneak into segments of DNA. Many of these are harmless, but some can cause health problems. Two or more genes can team up and change the outcome of a physical or molecular trait. This phenomenon, known as epistasis, occurs through complex interactions between genes that are functionally related—such as those that support protein creation.